{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-012546","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.076606+00:00","generated_at":"2026-05-26T22:23:13.115481+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organon FY2024 revenue $6.4B (+2%); guides FY2025 revenue $6.125-6.325B","bullets":["Full year 2024 revenue $6,401M (+2% as-reported, +3% constant currency); diluted EPS $3.33; non-GAAP adjusted diluted EPS $4.11.","Q4 revenue $1,592M flat YoY; net income $109M vs $546M (down 80%) due to prior-year one-time gain; adjusted net income $235M (+4%).","FY2025 guidance: revenue $6,125M-$6,325M (incl. ~$200M FX headwind); Adjusted EBITDA margin 31-32% (FY2024: 30.6%).","Biosimilars Q4 revenue down 18% on tender timing and U.S. pricing pressure; Women's Health flat as Nexplanon +12% offset NuvaRing decline.","Established Brands +2% driven by Emgality (Lilly license) and Vtama (Dermavant acquisition closed Oct 2024), partly offset by Atozet LOE."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-012546","json":"https://secwatch.observer/filing/0001104659-25-012546.json","markdown":"https://secwatch.observer/filing/0001104659-25-012546.md","text":"https://secwatch.observer/filing/0001104659-25-012546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925012546/0001104659-25-012546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925012546/tm256470d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:23:13.115481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}